SCHEMBL26467451

SCHEMBL26467451

C(/C=C/c1nc2ccccc2s1)=C\c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
APP P05067 1/20 0.57
INSR P06213 1/20 0.57
NCOA1 Q15788 1/20 0.57
NPC1 O15118 5/20 0.55
KDM4E B2RXH2 3/20 0.55
GAA P10253 2/20 0.55
CYP1A2 P05177 2/20 0.54
CYP2C19 P33261 2/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 3/20 0.49
POLB P06746 2/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11776645 1.00 MAPT (0.57) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL537849 0.89 MAPT (0.69) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL31063726 0.89 MAPT (0.69) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL537848 0.89 MAPT (0.69) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL26467491 0.89 MAPT (0.54) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL30434981 0.87 MEN1 (0.56) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL21889377 0.87 MEN1 (0.56) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL26094294 0.86 MEN1 (0.66) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL26467442 0.85 RAB9A (0.49) MAPTMEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL26467465 0.84 MAPT (0.49) MAPTMEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133538-A1 TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 MAPT, PSEN1, PSEN2 MAPT 1/4885MEN1 3624/4885KMT2A 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.